Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This pilot randomised single-blind trial evaluated whether adding high-frequency chest wall oscillation (HFCWO) via chest vest (ComfortCough II) to mechanical cough assist improves respiratory outcomes and reduces respiratory infections and hospital admissions compared to mechanical cough assist alone in patients with amyotrophic lateral sclerosis (ALS) receiving non-invasive ventilation.
Patients with amyotrophic lateral sclerosis (ALS) receiving non-invasive ventilation (NIV) at the Multidisciplinary ALS Unit of Hospital Universitario Virgen Macarena (Seville, Spain) were randomised to two parallel groups. The experimental group received high-frequency chest wall oscillation (HFCWO) via chest vest (ComfortCough II/CC20) combined with mechanical cough assist, while the control group received mechanical cough assist alone. The intervention period lasted 3 months, followed by 3 months of follow-up. Primary outcomes included respiratory infections and hospital admissions. Secondary outcomes included respiratory function, quality of life, sleep quality, and secretion clearance capacity. The study was approved by the Ethics Committee of Hospital Universitario Virgen Macarena - Virgen del RocÃo (code 2020-01) and sponsored by FISEVI (Fundación Pública Andaluza para la Investigación Biosanitaria de AndalucÃa).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| arm label Experimental: HFCWO plus mechanical cough assist | Experimental | Patients received high-frequency chest wall oscillation via chest vest (ComfortCough II) combined with mechanical cough assist for 3 months followed by 3 months follow-up. |
|
| Control: Mechanical cough assist alone | Active Comparator | Patients received mechanical cough assist alone for 3 months followed by 3 months follow-up. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| High-frequency chest wall oscillation (HFCWO) vest | Device | Chest wall oscillation vest delivering high-frequency vibrations to mobilise secretions, used in addition to mechanical cough assist device during the 3-month intervention period. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of respiratory infections | Number of respiratory infections requiring antibiotic treatment during the study period | 6 months (3 months intervention plus 3 months follow-up) |
| Measure | Description | Time Frame |
|---|---|---|
| Number of hospital admissions | Number of hospital admissions due to respiratory causes during the study period | 6 months (3 months intervention plus 3 months follow-up) |
| Measure | Description | Time Frame |
|---|---|---|
| Forced Vital Capacity (FVC) | Change in forced vital capacity percentage from baseline | 6 months |
| Peak Cough Flow (PCF) | Change in peak cough flow from baseline |
Inclusion Criteria:
exclusion criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Concepcion Romero Muñoz | Hospital Universitario Virgen Macarena | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital Universitario Virgen Macarena | Seville | Andalusia | 41009 | Spain |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Two parallel arms: experimental group receiving HFCWO chest vest combined with mechanical cough assist versus control group receiving mechanical cough assist alone. Randomised single-blind design.
Not provided
Not provided
Investigators assessing outcomes were blinded to treatment allocation. Blinding of participants and care providers was not feasible due to the nature of the intervention.
|
| Mechanical cough assist | Device | Mechanical insufflation-exsufflation device used alone for airway secretion clearance during the 3-month intervention period. |
|
|
| 6 months |
| Gait analysis | Change in gait parameters assessed by GAITRite electronic walkway system and correlation with respiratory function (FVC) | 6 months |
| ID | Term |
|---|---|
| D000690 | Amyotrophic Lateral Sclerosis |
| D012141 | Respiratory Tract Infections |
| ID | Term |
|---|---|
| D013118 | Spinal Cord Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D016472 | Motor Neuron Disease |
| D019636 | Neurodegenerative Diseases |
| D057177 | TDP-43 Proteinopathies |
| D009468 | Neuromuscular Diseases |
| D057165 | Proteostasis Deficiencies |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D007239 | Infections |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D035641 | Chest Wall Oscillation |
| ID | Term |
|---|---|
| D012138 | Respiratory Therapy |
| D013812 | Therapeutics |
Not provided
Not provided